Experience with type a botulinum toxin for treatment of outlet-type constipation

American Journal of Gastroenterology

Volumn 101, Issue 11, 2006, Pages 2570-2575

  Maria, Giorgio ^a   Cadeddu, Federica ^a   Brandara, Francesco ^a   Marniga, Gaia ^a   Brisinda, Giuseppe ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANORECTAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTESTINE CONTRACTION; MALE; PRIORITY JOURNAL; SPASTICITY;

BOTULINUM TOXIN TYPE A; CONSTIPATION; FEMALE; HUMANS; INJECTIONS; MALE; MANOMETRY; MIDDLE AGED; PELVIC FLOOR;

EID: 33750502021     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00791.x     Document Type: Article

References (34)

1. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-8.
2. Talley NJ, Jones M, Nuyts G, et al. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003;98:1107-11.
3. Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S3-10.
4. Talley NJ. Chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S1-2.
5. Talley NJ. Management of chronic constipation. Rev Gastroenterol Disord 2004;4:18-24.
6. Garrigues V, Galvez C, Ortiz V, et al. Prevalence of constipation: Agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and selfreported definition in a population-based survey in Spain. Am J Epidemiol 2004;159:520-6.
7. Thompson WG. The road to Rome. Gut 1999;45(suppl 2):II80-1.
8. Maria G, Sganga G, Civello IM, et al. Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders. Br J Surg 2002;89:950-61.
9. Brisinda G, Cadeddu F, Maria G. Chronic constipation. N Engl J Med 2004;350:1259-60.
10. Albanese A, Brisinda G, Mathias CJ. The autonomic nervous system and gastrointestinal disorders. In: Appenzeller O, ed. Handbook of clinical neurology. The autonomic nervous system. Part II. Dysfunctions. 2nd Ed. New York: Elsevier Science B.V., 2000:613-63.
11. Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: A dystonic phenomenon? J Neurol Neurosurg Psychiatry 1988;51:1503-7.
12. Schiller LR. The therapy of constipation. Aliment Pharmacol Ther 2001;15:749-63.
13. Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S43-51.
14. Wald A. Pathophysiology, diagnosis and current management of chronic constipation. Nat Clin Pract Gastroenterol Hepatol 2006;3:90-100.
15. DiPalma JA. Current treatment options for chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S34-42.
16. Addison R, Davies C, Haslam D, et al. A national audit of chronic constipation in the community. Nurs Times 2003;99:34-5.
17. Stessman M. Biofeedback: Its role in the treatment of chronic constipation. Gastroenterol Nurs 2003;26:251-60.
18. Enck P. Biofeedback training in disordered defecation. A critical review. Dig Dis Sci 1993;38:1953-60.
19. Ferrara A, De Jesus S, Gallagher JT, et al. Time-related decay of the benefits of biofeedback therapy. Tech Coloproctol 2001;5:131-5.
20. Nyam DC, Pemberton JH, Ilstrup DM, et al. Long-term results of surgery for chronic constipation. Dis Colon Rectum 1997;40:273-9.
21. Hallan RI, Williams NS, Melling J, et al. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1988;2:714-7.
22. Shafik A, El Sibai O. Botulin toxin in the treatment of non-relaxing puborectalis syndrome. Dig Surg 1998;15:347-51.
23. Joo JS, Agachan F, Wolff B, et al. Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 1996;39:1107-11.
24. Guideline for chronic constipation management. J Fam Pract 2005;54:932.
25. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100(suppl 1):S1-4.
26. Wexner SD, Cheape JD, Jorge JM, et al. Prospective assessment of biofeedback for the treatment of paradoxical puborectalis contraction. Dis Colon Rectum 1992;35:145-50.
27. Wiesel PH, Dorta G, Cuypers P, et al. Patient satisfaction after biofeedback for constipation and pelvic floor dyssynergia. Swiss Med Wkly 2001;131:152-6.
28. Pfeifer J, Agachan F, Wexner SD. Surgery for constipation: A review. Dis Colon Rectum 1996;39:444-60.
29. Maria G, Anastasio G, Brisinda G, et al. Treatment of puborectalis syndrome with progressive anal dilation. Dis Colon Rectum 1997;40:89-92.
30. Ron Y, Avni Y, Lukovetski A, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 2001;44:1821-6.
31. Albanese A, Brisinda G, Bentivoglio AR, et al. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003;98:1439-40.
32. Albanese A, Maria G, Bentivoglio AR, et al. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord 1997;12:764-6.
33. Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson's disease: Results of botulinum toxin treatment. Aliment Pharmacol Ther 2005;22:997-1003.
34. Brisinda G, Cadeddu F, Brandara F, et al. Management of defecation disorders with botulinum neurotoxin. Aliment Pharmacol Ther 2004;19:1131-3.